I imagine George Yancopoulos, profiled on this month’s cover, to have gained some of his life’s wisdom in a similar fashion to most people — by trying new things.
Tawni Koutchesfahani, director of manufacturing strategy at Relypsa, says pharmaceutical manufacturing must diversify if it is to thrive. That means the recruitment and retention of more women and more millennials.
Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.
An exclusive interview with George Yancopoulos who talks about why his partnership with Len Schleifer has lasted so long and how “wild ideas” have served as the underlying theme to Regeneron.
Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.
According to Victoria DiBiaso, global head of clinical operations strategy and collaboration at Sanofi, “When it comes to improving trials, you have to look at protocol optimization. For us, that is where it all begins.
According to Anne White, Lilly’s VP of next generation development and project management, for the past three years the company has steadily worked toward finding a way to get its medicines to patients faster.
Michael Bonney discusses his new role as the CEO of a microbiome focused drug development startup — Kaleido Biosciences.
Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.
In 2018, Alnylam seems poised to deliver its first big breakthrough. John Maraganore, CEO, sat down with LSL Chief Editor, Rob Wright, to share his perspectives on Alnylam’s upcoming year — including the good, the bad, and everything in-between.
Clay Siegall, Ph.D., president, CEO, and chairman of Seattle Genetics, gives an exclusive interview about his company’s potential blockbuster, how they got to this point, and what’s next.
Vinita Kumar, VP of quality at Versartis, talks about how her philosophy on CMO collaboration has been field-tested. “Never does that importance of real collaboration reveal itself more than in hard times for your program when you need it most,” she says.
With TEVA Pharmaceuticals out of the picture, Mesoblast had to figure out how to survive. Due to hard work, Mesoblast found a way to save their company and here is how they did it. “The termination left us in a hole. We had to gather our thoughts, allocate resources, and prove that the technology worked.”
“A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.
The CEO of Sage Therapeutics, Jeff Jonas, M.D., elaborates on the company’s approach of developing small clinical trials.
Sage Therapeutics’ CEO Jeff Jonas, M.D., discusses what he means by a “return to the basics of science” at his company.
Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses some of the challenges of launching a product that could change the paradigm of treating postpartum depression (PPD).
BIO 2018 does more than make business meeting history, but facilitates personal connections that can lead toward doing better business.
Miriam Massaad, a biomedical engineering student at Boston University, shares her experiences as a first-time attendee at the 2018 BIO International Convention and Conference in Boston.
